Advertisement
APLM vs SNTI
Which Stock Would AI Choose? Apollomics (APLM) vs. Senti Biosciences (SNTI) Stock Comparison
Key Takeaways
- Different clinical stages and market caps: APLM trades at a materially higher share price and market capitalization than SNTI, despite both being clinical-stage biotechnology companies.
- Distinct therapeutic focus: APLM concentrates on small-molecule oncology inhibitors, while SNTI develops "logic-gated" cell therapies led by SENTI-202, a CAR-NK candidate for blood cancers.
- Contrasting liquidity and listing risk: SNTI has faced Nasdaq non-compliance notices tied to its bid price and stockholders' equity, an overhang APLM has not recently reported.
- Financing and insider activity: APLM has drawn support from insider buying and convertible-note financing, while SNTI has pursued strategic financing and a corporate reorganization.
- Volatility is a shared feature: Both names have shown sharp price swings in recent weeks, a common trait of micro-cap, pre-revenue drug developers.
- For more detail on each name, explore APLM Major News and APLM Today's Price Move, as well as SNTI Major News and SNTI Today's Price Move.
- To see how automated systems are positioning across the market, explore Trending AI Robots.
Introduction
Both APLM (Apollomics Inc.) and SNTI (Senti Biosciences Holdings, Inc.) are clinical-stage biotechnology companies pursuing cancer therapies, yet they occupy very different positions in the market. Apollomics is a small-molecule oncology developer, while Senti Biosciences engineers cell and gene therapies. This stock comparison is most relevant to investors and traders who follow speculative, high-risk biotech names where clinical catalysts, financing decisions, and regulatory milestones drive relative performance. Because both companies are pre-revenue or near pre-revenue and carry elevated volatility, understanding their contrasting business models, cash positions, and momentum is essential before assessing their market positioning.
APLM Overview and Recent Performance
APLM is a clinical-stage biopharmaceutical company focused on targeted oncology therapies, operating research and development activities in the United States and China. Its pipeline is built around tumor inhibitors such as vebreltinib, a selective c-Met inhibitor, alongside earlier-stage immuno-oncology candidates. In recent market activity, the stock has experienced significant price swings, with a wide 52-week range that reflects both periods of sharp gains and sharp pullbacks.
Sentiment around APLM has been influenced by several developments. Insider buying, including share purchases by the company's chief executive, has signaled internal confidence, and the company secured convertible-note financing to support operations. For its 2025 fiscal year, APLM reported roughly $8.5 million in revenue, largely from licensing, and a net loss that narrowed considerably from the prior year. These factors, combined with the stock's small float, have contributed to elevated volatility in recent weeks.
SNTI Overview and Recent Performance
SNTI is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its Gene Circuit platform. Its lead candidate, SENTI-202, is an off-the-shelf CAR-NK cell therapy designed to target blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The program has received orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration (FDA).
In recent quarters, SNTI reported a reduced net loss, supported by lower operating expenses and a non-recurring lease modification gain, and announced positive FDA feedback supporting a pivotal trial design for SENTI-202. However, the stock has faced substantial pressure, trading near historic lows. The company received Nasdaq non-compliance notices relating to its bid price and minimum stockholders' equity requirement, and it has pursued a corporate reorganization and strategic financing, including contingent value rights (CVRs) tied to SENTI-202 milestones. These factors have driven pronounced downside volatility in recent weeks.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's automated trading systems. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, yet only those best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance record, and universe of tickers, so no two systems behave identically. For traders evaluating names like APLM and SNTI, reviewing these bots can provide a data-driven perspective on momentum, trend consistency, and risk. Explore the Trending AI Robots page to see which automated strategies are currently positioned most favorably.
Head-to-Head Comparison
The clearest contrast between APLM and SNTI lies in their business models and near-term risk profiles. APLM pursues oral, small-molecule inhibitors with a geographically diversified footprint, while SNTI relies on a single lead cell-therapy program whose clinical and regulatory progress dominates its valuation. APLM has recently reported licensing revenue and a meaningfully narrowed loss, whereas SNTI remains essentially pre-revenue.
On market positioning, APLM's insider buying and financing activity have provided support, while SNTI contends with Nasdaq listing-compliance deadlines and shareholder dilution from reorganizations. Both stocks carry micro-cap liquidity risk and sensitivity to single-catalyst news flow, but the nature of that risk differs: APLM's is tied to pipeline breadth and financing runway, while SNTI's is concentrated in SENTI-202's clinical execution and its ability to regain listing compliance.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative share-price stability, financing activity, and the presence of ongoing regulatory overhangs, Tickeron's AI would likely favor APLM over SNTI in the current environment. APLM's higher price level, insider buying, narrowed losses, and absence of reported listing-compliance notices point to comparatively stronger near-term positioning. SNTI's promising RMAT-designated program is offset by bid-price and equity compliance challenges and pronounced downside momentum. This view is probabilistic and reflects current conditions rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLM is a Hold and SNTI is a Hold.
APLM in -16.20% downward trend, declining for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where APLM declined for three days, in 223 of 249 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APLM as a result. In 74 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for APLM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 26 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
The 10-day moving average for APLM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for APLM entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where APLM's RSI Indicator exited the oversold zone, 18 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where APLM advanced for three days, in 140 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
APLM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. APLM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.704) is normal, around the industry mean (3.498). P/E Ratio (-1.287) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.761) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SNTI in -12.12% downward trend, declining for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SNTI declined for three days, in 273 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNTI as a result. In 76 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for SNTI turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The Aroon Indicator for SNTI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for SNTI's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.498). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| APLM | SNTI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 2 days ago 88% |
| Stochastic ODDS (%) | 1 day ago 61% | 2 days ago 72% |
| Momentum ODDS (%) | 1 day ago 70% | 2 days ago 75% |
| MACD ODDS (%) | 1 day ago 54% | 2 days ago 87% |
| TrendWeek ODDS (%) | 1 day ago 82% | 2 days ago 84% |
| TrendMonth ODDS (%) | 1 day ago 88% | 2 days ago 82% |
| Advances ODDS (%) | 14 days ago 80% | 14 days ago 82% |
| Declines ODDS (%) | 7 days ago 90% | 2 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 81% | 2 days ago 83% |
| Aroon ODDS (%) | 1 day ago 89% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APLM’s FA Score shows that 0 FA rating(s) are green while SNTI’s FA Score has 1 green FA rating(s).
- APLM’s FA Score: 0 green, 5 red.
- SNTI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APLM’s TA Score shows that 4 TA indicator(s) are bullish while SNTI’s TA Score has 4 bullish TA indicator(s).
- APLM’s TA Score: 4 bullish, 6 bearish.
- SNTI’s TA Score: 4 bullish, 4 bearish.
Price Growth
APLM (@Biotechnology) experienced а -10.66% price change this week, while SNTI (@Biotechnology) price change was -20.97% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
SNTI is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
APLM and
Correlation & Price change
A.I.dvisor indicates that over the last year, APLM has been loosely correlated with SNTI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if APLM jumps, then SNTI could also see price increases.
| Ticker / NAME | Correlation To APLM | 1D Price Change % | ||
|---|---|---|---|---|
| APLM | 100% | -3.05% | ||
| SNTI - APLM | 47% Loosely correlated | +11.81% | ||
| HCWB - APLM | 45% Loosely correlated | -6.75% | ||
| PRAX - APLM | 39% Loosely correlated | +2.55% | ||
| MGX - APLM | 37% Loosely correlated | +8.04% | ||
| IPHA - APLM | 36% Loosely correlated | +4.61% | ||
More | ||||